China Research and Intelligence (CRI) has emerged to provide high-level research and advisory services to all those with keen interest in different Chinese markets and industries. The firm, founded in 2007, is headquartered in Shanghai, China. Their team’s principle goal is to present the most helpful and reliable insights and information, sincerely serving a broad choice of multinational and local customers with their business practice and ethics.
CRI’s reports are packed with precise analysis of key market indicators, strategic recommendations from industry experts, market estimated figures, projections, reviews of competitive strategies, consumers investigation, reviews of business models, market share analyses, key forces driving of restraining market growth.
CRI’s scope of offerings encircles numerous market research reports, industry analytical reviews, company business reports, industry-specific research databases. Further, the company also offers outsource and custom-tailored services for research organisations, and multiple report readers.
Publications found:
1,365
Sort by:
Investigation Report on China Thymosin ?1 Market, 2010-2019
US$ 2,000.00
... Diao Group, Suzhou Tianma Pharma Group Tianji BIO-pharmaceutical Co., Ltd and Hainan Shuangcheng Pharmaceuticals Co., Ltd, among which Diao Group has the largest market share of about 36% for sales volume in 2014. However, Patheon Italia ...
June 2015
30 pages
Investigation Report on China Sodium Ibandronate Market, 2010-2019
US$ 2,000.00
... China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical ...
June 2015
30 pages
Investigation Report on China Raloxifene Market, 2010-2019
US$ 2,000.00
... bone mass or osteoporosis while this figure is 30%-50% among women aged 60 and above. Raloxifene (raloxifene hydrochloride), a non-hormone drug against bone resorption, belongs to the second generation of selective estrogen receptor modulator (SERMs ...
June 2015
30 pages
Investigation Report on China Levofloxacin Market, 2010-2019
US$ 2,000.00
... Daiichi Sankyo Co., Ltd (Beijing), Yangtze River Pharmaceutical Group, China Resources Double Crane Pharmaceutical Co., Ltd, Santen Pharmaceutical Co., Ltd (Japan) and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory have occupied the majority of the market share, among which Daiichi Sankyo ...
June 2015
40 pages
Investigation Report on China Simvastatin Market, 2010-2019
US$ 2,000.00
... Pharmaceutical Co., Ltd, Merck Sharp & Dohme (UK), Guangzhou Nanxin Pharmaceutical Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Shandong Lukang Pharmaceutical Co., Ltd occupy the majority of market, among which Hangzhou MSD Pharmaceutical Co., Ltd ...
June 2015
40 pages
Investigation Report on China Risedronate Sodium Market, 2010-2019
US$ 2,000.00
... Risedronate sodiums in the Chinese market are all produced by local enterprises represented by Kunming Jida Pharmaceutical Co., Ltd, Topfond, Yangtze River Pharmaceutical Group, Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd and Beijing SL Pharm, among which Kunming Jida Pharmaceutical Co., Ltd ...
June 2015
30 pages
Investigation Report on China Thrombin Market, 2010-2019
US$ 2,000.00
... thrombin in the Chinese market are Changchun Guoao Pharmaceutical Co., Ltd, Biochemical Pharmaceutical Factory of Zhuhai S. E. Z., Hunan Yige Pharmaceutical Co., Ltd, Hacon Pharma and Wuxi Kaifu Pharmaceutical Co., Ltd ...
June 2015
35 pages
Investigation Report on China Piperacillin Sodium and Tazobactam Sodium Market, 2010-2019
US$ 2,000.00
... Wyeth Pharmaceutical Co., Ltd (US), Qilu Pharmaceutical Co., Ltd, North China Pharmaceutical Group Corporation, Zhejiang Anglikang Pharmaceutical Co., Ltd and United Laboratories occupy the majority of the Chinese market, among which Wyeth Pharmaceutical Co., Ltd ...
June 2015
35 pages
Investigation Report on China Bromhexine Market, 2010-2019
US$ 2,000.00
... bromhexine in the Chinese market mainly comes from local enterprises like Jiangxi Kelun Pharmaceutical Co., Ltd, Jincheng Haisi Pharmaceutical Co., Ltd and Shanxi Powerdone Pharmaceutical Co., Ltd, Shijiazhuang No.4 Pharmaceutical Co., Ltd ...
June 2015
30 pages
Investigation Report on China Entecavir Market, 2010-2019
US$ 2,000.00
... hepatitis B virus (HBV) exceeds 100 million in China, among which 20-30 million suffering from chronic Hepatitis B. ... entecavir in China rose from CNY 30 million in 2006 to CNY 1.207 billion in 2014 and CAGR during this period reached up to 55%. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd ...
June 2015
30 pages
Investigation Report on China Ganglioside Market, 2010-2019
US$ 2,000.00
... ganglioside sodium in China, among which Qilu Pharmaceutical Co., Ltd, Medical University Pharmaceutical Co., Ltd, Beijing Science Sun Pharmaceutical Co., Ltd, Changchun Xiangtong Pharmaceutical Co., Ltd and Wellso Pharmaceutical take the lion’s share. The marketing of domestic ganglioside ...
June 2015
35 pages
Investigation Report on China Glucosamine Market, 2010-2019
US$ 2,000.00
... Glucosamine is of great demand in China. Most of the market share has been occupied by Shanxi Zhongyuanwei Pharmaceutical Co., Ltd, Bright Future Pharmaceutical Laboratories Limited, Rottapharm Ltd, Zhejiang Hisun Pharmaceutical Co., Ltd ...
June 2015
35 pages
Investigation Report on China Levothyroxine Market, 2010-2019
US$ 2,000.00
... Thyroid hormones (TH) have the greatest effect of promoting growth on five-month-old babies or younger ones. Without thyroid hormones ... Levothyroxine enjoys a vast demand in China. Merck (Germany), Berlin-Chemie AG (Germany) and China Associated Pharmaceutical all take up certain market share, among which Merck ...
June 2015
20 pages
Investigation Report on China Menotropins Market, 2010-2019
US$ 2,000.00
... Livzon Pharmaceutical, Livzon Pharmaceutical Group, Inc, Ferring Pharmaceytical Co., Ltd (Germany), Ma’anshan Fengyuan Pharmaceutical Co., Ltd, Yantai North Pharmaceutical Co., Ltd and Shanghai Livzon Pharmaceutical Co., Ltd, among which Shanghai Livzon Pharmaceutical Co., Ltd ...
June 2015
30 pages
Investigation Report on China Moxifloxacin Market, 2010-2019
US$ 2,000.00
... China are mainly produced by Nanjing Youke Pharmaceutical CO., Ltd and The Bayer Group whichowns the larger market share of over 95% for sales value in 2014. As an outstanding antibacterial drug, moxifloxacin ...
June 2015
20 pages
Investigation Report on China Ossotide Market, 2010-2019
US$ 2,000.00
... of rheumatoid arthritis (RA) is 0.2%-0.36% and the number of cases is 5-10 million in China. Apart from RA, osteoarthritis, an expression of ... ossotide in China competitive landscape of ossotide in Chinese market price of ossotide made by different enterprises in China market outlook of ossotide in China ...
June 2015
35 pages
Investigation Report on China Progesterone Market, 2010-2019
US$ 2,000.00
... progesterone in the Chinese market is imported and made by Fleet (UK) and Capsugel(FR). The rest mainly comes from such local manufacturers as Asen, Zhejiang Xianju Pharmaceutical Co., Ltd ... steroid drugs will keep growing and that with the development of downstream products, the demand for progesterone ...
June 2015
35 pages
Investigation Report on China Rosuvastatin Market, 2010-2019
US$ 2,000.00
... rosuvastatin (rosuvastatin calcium ... rosuvastatin in the Chinese market mainly come from the following companies: IPR Pharmaceuticals (US), Lunan Better Pharmaceutical Co., Ltd, Nanjing Chia Tai Tianqing, Simcere and Zhejiang Jingxin Pharmaceutical Co., Ltd, among which IPR Pharmaceuticals ...
June 2015
35 pages
Investigation Report on China Atorvastatin Market, 2010-2019
US$ 2,000.00
... in the near future. Atorvastatin, a common drug that can lower blood cholesterol levels, was developed by Pfizer under the trade name of Lipitor. Boasting of nearly ... miracle among all the medicines for sale. After entering China, atorvastatin develops fast with annual sales value rising from less ...
June 2015
30 pages
Investigation Report on China Tacrolimus Market, 2010-2019
US$ 2,000.00
... Tacrolimus (also FK506) is a macrolide lactone immunosuppressive drug discovered from a soil sample that contained the bacterium Streptomyces tsukubaensis in 1984 by Fujisawa Pharmaceutical Co., Ltd. Tacrolimus ...
June 2015
30 pages
Investigation Report on China Insulin Lispro Market, 2010-2019
US$ 2,000.00
... : market size of insulin lispro in China market share of manufacturers of Insulin Lispro in China retail price of insulin lispro in Chinese market major manufacturers of insulin lispro in Chinese market market outlook of insulin lispro in China The author suggests ...
June 2015
20 pages
Investigation Report on China Capecitabine Market, 2010-2019
US$ 2,000.00
... name of Xeloda and then spread through over 80 countries and regions in 2 years. In Mar. 2001, capecitabine entered China to be clinically used for the treatment of advanced breast cancer, colorectal cancer and other solid tumors. The chemotherapy for colorectal cancer ...
June 2015
30 pages
Investigation Report on China Celecoxib Market, 2010-2019
US$ 2,000.00
... the market. In Sep. 2000, celebrex (celecoxib capsule) made by Pfizer Inc was approved by CFDA to enter China. Celecoxib develops fast then, ... celecoxib in Chinese market market outlook of celecoxib in China The author suggests the following groups of people purchase this report: manufacturers of NSAIDs ...
June 2015
20 pages
Investigation Report on China Desloratadine Market, 2010-2019
US$ 2,000.00
... desloratadine in China market share of manufacturers of desloratadine in China price of desloratadine in Chinese market major manufacturers of desloratadine in Chinese market market outlook of desloratadine in China ...
June 2015
30 pages
Investigation Report on China Doxofylline Market, 2010-2019
US$ 2,000.00
... doxofylline in China market share of manufacturers of doxofylline in China price of doxofylline in Chinese market major manufacturers of doxofylline in Chinese market market outlook of doxofylline in China ...
June 2015
30 pages
Investigation Report on China Ezetimibe Market, 2010-2019
US$ 2,000.00
... estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive ... this report: market size of ezetimibe in China price of ezetimibe in Chinese market market outlook of ezetimibe in China The author suggests the following groups ...
June 2015
20 pages
Investigation Report on China Liraglutide Market, 2011-2019
US$ 2,000.00
... diabetes incidence in China. Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, was developed by Novo Nordisk in 2008 to treat diabetes. Liraglutide, a derivative attained by attaching a fatty acid molecule to GLP-1 molecule, can reduce the HbA1c level and weight of type 2 diabetes ...
June 2015
25 pages
Investigation Report on China Methylprednisolone Market, 2010-2019
US$ 2,000.00
... varieties of steroid’s APIs, half are made in China. As a variety performing well in hospitals in recent years, methylprednisolone, ... methylprednisolone entered China in the late 1990s under the trade names of Medrol (Pfizer) and Solu-Medrol (Pharmacia & Upjohn). The APIs and preparations of methylprednisolone ...
June 2015
30 pages
Investigation Report on China Octreotide Market, 2010-2019
US$ 2,000.00
... octreotide in China market share of manufacturers of octreotide in China price of octreotide in Chinese market major manufacturers of octreotide in Chinese market market outlook of octreotide in China ...
June 2015
30 pages
Investigation Report on China Recombinant Factor ? Market, 2010-2019
US$ 2,000.00
... and treatment of hemophilia have a huge market. Apart from Bayer Schering, Baxter and Wyeth also make recombinant factor Ⅷ too. After entering China, recombinant factor Ⅷ develops ... report: sales status of recombinant factor Ⅷ in China price of recombinant factor Ⅷ in Chinese market major manufacturers of recombinant factor Ⅷ in Chinese market share of dosage forms of recombinant factor Ⅷ in China market outlook of recombinant factor Ⅷ in China The author suggests ...
June 2015
30 pages
Investigation Report on China Tiotropium Bromide Market, 2010-2019
US$ 2,000.00
... tiotropium bromide in Chinese hospitals price of tiotropium bromide in Chinese hospitals major manufacturers of tiotropium bromide in Chinese market share of different dosage forms of tiotropium bromide in Chinese hospitals market outlook of tiotropium bromide in China ...
June 2015
20 pages
Investigation Report on China Olmesartan Market, 2010-2019
US$ 2,000.00
... hypertension is a controllable disease. In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil ... ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China ...
June 2015
20 pages
Investigation Report on China Insulin Detemir Market, 2010-2019
US$ 2,000.00
... insulin detemir in Chinese market price of insulin detemir in Chinese market major manufacturers of insulin detemir in China share of different dosage forms of insulin detemir in Chinese market market outlook of insulin detemir in China ...
June 2015
20 pages
Investigation Report on China Linezolid Market, 2010-2019
US$ 2,000.00
... Linezolid, a synthetic oxazolidinone, was developed by Pharmacia & Upjohn. In 2000, it was approved by FDA to be used for infection caused by gram-positive ... China, linezolid market has long been monopolized by foreign pharmaceutical corporations. Since the patent for linezolid ...
June 2015
20 pages
Investigation Report on China Nifuratel Market, 2010-2019
US$ 2,000.00
... under the trade names of Macmiror and Macmiror Complex. Nifuratel develops fast after entering China with annual sales rising ... of nifuratel in Chinese market market outlook of nifuratel in China The author suggests the following groups of people purchase this report: manufacturers of gynecological ...
June 2015
30 pages
Investigation Report on China Oxiracetam Market, 2010-2019
US$ 2,000.00
... Senile dementia poses a serious threat to old people. According to statistics, about 10% of people aged above 60 suffer from senile dementia, among which 5% have Alzheimei’s Disease (AD). In China, the number of senile dementia ...
June 2015
30 pages
Investigation Report on China Phosphocreatine Market, 2010-2019
US$ 2,000.00
... market share compared with other cardiovascular drugs. According to CRI’s survey, phosphocreatine develops fast after entering China with annual sales value rising ... of phosphocreatine in Chinese market market outlook of phosphocreatine in China The author suggests the following groups of people purchase this report: manufacturers of drugs for cardiovascular disease investors ...
June 2015
30 pages
Investigation Report on China Rivaroxaban Market, 2010-2019
US$ 2,000.00
... After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter ... rivaroxaban in Chinese hospitals price of rivaroxaban in Chinese hospitals major manufacturers of rivaroxaban share of different dosage forms of rivaroxaban in Chinese hospitals market outlook of rivaroxaban in China ...
June 2015
20 pages
Investigation Report on China Tamsulosin Market, 2010-2019
US$ 2,000.00
... and prostate and reducing urethral pressure, but it can’t cure BPH. Compared with other α1-adrenergic receptor blockers, tamsulosin ... Boehringer Ingelheim. Prostate drug market is highly concentrated in China. Three kinds of prostate drugs – finasteride, tamsulosin and prostat which occupy over 90% of prostate ...
June 2015
30 pages
